Vir Biotechnology, Inc. (VIR) stock price, financials & research

Regular session · ET · Market data may be delayed.

GoAI snapshot

Jul 10, 2026

33/ 100

GoAI Score

Sell

Valuation

2

Overpriced

Sentiment

68

Bullish

Risk

53

Elevated Risk

Momentum

63

Gaining

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

Company profile

Industry: Biotechnology
Sector: Healthcare
Headquarters: US

Market position

Volume: 3.07M
Market cap: 1.88B USD

Financials

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin

Income trends

Revenue

68.56M USD-7.61%

Operating income

−468.02M USD+10.58%

Net income

−437.99M USD+16.09%

Financial statements: Income statement
Metric (USD)	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	68.56M USD	74.21M USD	86.18M USD	1.62B USD	1.1B USD
Cost of goods sold	11.71M USD	15.4M USD	22.22M USD	161.81M USD	71.68M USD
Gross profit	56.85M USD	58.8M USD	63.96M USD	1.45B USD	1.02B USD
Research and development	432.8M USD	463.19M USD	550.92M USD	467.87M USD	442.2M USD
Selling, general, and administrative	92.07M USD	119.03M USD	174.05M USD	153.05M USD	160.79M USD
Operating expenses	524.87M USD	582.22M USD	724.97M USD	620.92M USD	602.99M USD
Interest income	40.24M USD	71.81M USD	86.99M USD	28.09M USD	439K USD
Depreciation and amortization	11.68M USD	14.56M USD	19.45M USD	15.49M USD	11.98M USD
Operating income	−468.02M USD	−523.42M USD	−661.01M USD	833.07M USD	420.75M USD
Net income	−437.99M USD	−521.96M USD	−615.06M USD	515.84M USD	528.58M USD

Company facts updated Oct 9, 2026.

Earnings

EPS beat rate: 45%; 5 beats, 6 misses, 0 met estimates
Average EPS surprise: -763.84%; 11 comparable reports
Latest EPS result: 0.47; Estimate 0.33 · Beat by 41.31%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$23.50

111.33% upside

Past 12 months12-month forecastHigh $25.00Average $23.50Low $22.00

VIR news

businesswire.comOct 8, 2026

Vir Biotechnology Announces PSMA-targeted PRO-XTEN® Dual-masked T-cell Engager VIR-5500 Received FDA Fast Track Designation for the Treatment of Prostate Cancer

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to VIR-5500, a PSMA-targeted PRO-XTEN® dual-masked…

Read source

defenseworld.netOct 8, 2026

uniQure (NASDAQ:QURE) and Vir Biotechnology (NASDAQ:VIR) Critical Review

Vir Biotechnology (NASDAQ: VIR - Get Free Report) and uniQure (NASDAQ: QURE - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the…

Read source

gurufocus.comOct 7, 2026

Vir Biotechnology Appoints David Liu as Chief Medical Officer

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of David Liu, M.D., Ph.D., as Executive Vice President and Chief Medical Officer (CMO), ef

Read source

businesswire.comOct 7, 2026

Vir Biotechnology Appoints David Liu as Chief Medical Officer

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of David Liu, M.D., Ph.D., as Executive Vice President and Chief Medical Officer (CMO), effective October 12, 2026.…

Read source

businesswire.comOct 5, 2026

Vir Biotechnology to Present Expanded Phase 2 SOLSTICE Results for Elebsiran and Tobevibart in Hepatitis Delta at AASLD's The Liver Meeting® 2026

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will present data from the Phase 2 SOLSTICE trial evaluating the combination of elebsiran and tobevibart for chronic…

Read source

businesswire.comOct 1, 2026

Vir Biotechnology Appoints Aziz Sawaf as Chief Financial Officer

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology Appoints Aziz Sawaf as Chief Financial Officer.

Read source

VIR peers

AMGN

Amgen Inc.

$406.36

-0.27%

GILD

Gilead Sciences, Inc.

$146.61

-0.33%

ISRG

Intuitive Surgical, Inc.

$417.25

+0.44%

VRTX

Vertex Pharmaceuticals Incorporated

$503.53

+0.06%

SNY

Sanofi

$40.1521

-0.19%

MRNA

Moderna, Inc.

$197.41

+0.21%

Vir Biotechnology, Inc.

VIR company overview

Vir Biotechnology, Inc.

VIR company overview

GoAI snapshot

Company profile

Market position

Financials

Financial statements

Margin trends

Income trends

Earnings

EPS: actual versus estimate

Revenue: actual versus estimate

Analyst ratings

Analyst price target

VIR news

Vir Biotechnology Announces PSMA-targeted PRO-XTEN® Dual-masked T-cell Engager VIR-5500 Received FDA Fast Track Designation for the Treatment of Prostate Cancer

uniQure (NASDAQ:QURE) and Vir Biotechnology (NASDAQ:VIR) Critical Review

Vir Biotechnology Appoints David Liu as Chief Medical Officer

Vir Biotechnology Appoints David Liu as Chief Medical Officer

Vir Biotechnology to Present Expanded Phase 2 SOLSTICE Results for Elebsiran and Tobevibart in Hepatitis Delta at AASLD's The Liver Meeting® 2026

Vir Biotechnology Appoints Aziz Sawaf as Chief Financial Officer

VIR peers

Continue in GoAI

VIR company overview

Company profile

Market position

VIR company overview

VIR company overview

Company profile

Market position

VIR company overview

GoAI snapshot

Company profile

Market position

Financials

Financial statements

Margin trends

Income trends

Earnings

EPS: actual versus estimate

Revenue: actual versus estimate

Analyst ratings

Analyst price target

VIR news

Vir Biotechnology Announces PSMA-targeted PRO-XTEN® Dual-masked T-cell Engager VIR-5500 Received FDA Fast Track Designation for the Treatment of Prostate Cancer

uniQure (NASDAQ:QURE) and Vir Biotechnology (NASDAQ:VIR) Critical Review

Vir Biotechnology Appoints David Liu as Chief Medical Officer

Vir Biotechnology Appoints David Liu as Chief Medical Officer

Vir Biotechnology to Present Expanded Phase 2 SOLSTICE Results for Elebsiran and Tobevibart in Hepatitis Delta at AASLD's The Liver Meeting® 2026

Vir Biotechnology Appoints Aziz Sawaf as Chief Financial Officer

VIR peers

Continue in GoAI